Monitor for complete Phase 1/2 SLE and SSc data at EULAR 2026 (June 3-6) and the initiation of the SSc-ILD registrational cohort in 4Q26. The next major catalyst is the myositis registrational data in mid-2027; near-term trading will likely be driven by pipeline updates at medical conferences.
Price Chart
Executive Summary
Cabaletta Bio reported Q2 2026 net loss of $-0.34 per share, which is in line with the consensus estimate of $-0.37 (a 8.1% beat). The company highlighted progress in its registrational myositis trial (data mid-2027, BLA 2H27) and plans to initiate a second registrational cohort in SSc-ILD in 4Q26. Cash position strengthened to $225.1M post a $150M May offering, extending runway into mid-2027. The filing is neutral as the EPS surprise is modest and the pipeline milestones are distant, with no change to the pre-existing narrative.
Key Financial Metrics
Key Facts
- Net loss per share was $-0.34 for Q2 2026, compared to $-0.73 in Q2 2025.
- Cash, cash equivalents, and short-term investments were $225.1M as of June 30, 2026.
- Registrational RESET-Myositis data on track for mid-2027 to support a BLA submission in 2H27.
- Second registrational cohort in SSc-associated ILD anticipated to initiate in 4Q26.
- PC-free approach being incorporated in RESET-MG; higher-dose cohorts enrolling in RESET-PV and RESET-SLE.
- ElevateBio selected as second CDMO for clinical and commercial manufacturing.
Financial Impact
Q2 2026 net loss of $51.0M, R&D expenses $44.4M (up 18% YoY), cash position $225.1M (up 69% from Dec 2025).
Risk Factors
- Clinical trial failure or delays in myositis or SSc registrational cohorts.
- Competitive landscape from other CAR-T therapies in autoimmune indications.
- Dependence on successful manufacturing scale-up with Cellares and ElevateBio.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759138-26-000038 |
| Document: caba-20260813.htm | 0001759138-26-000038 |
| Document: 0001759138-26-000038-index-headers.html | 0001759138-26-000038 |
| Document: 0001759138-26-000038-index.html | 0001759138-26-000038 |
| Document: 0001759138-26-000038.txt | 0001759138-26-000038 |
| 8-K Data (Synthetic) | 0001759138-26-000038 |
Track record
29 reports on CABA
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers